Treatment of mucositis
AssigneeRxKinetix, Inc.
InventorsGary J. Rosenthal, Jeffrey B. Etter, Timothy C. Rodell, Wren H. Schauer, Adrian Samaniego
Life of this patent
Estimating the term…
Abstract
This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.
Claims23
A method for treatment of oral mucositis in an oral cavity of a host as a side effect of the host undergoing cancer therapy treatment, the cancer therapy treatment comprising one or both of chemotherapy and radiation therapy, the method comprising:
- introducing a therapeutic composition into the oral cavity of the host, the therapeutic composition comprising:
- (i) a reverse-thermal gelation biocompatible polymer that is a polyoxyalkylene block copolymer, comprising at least one block of a first polyoxyalkylene and at least one block of a second polyoxyalkylene that is different than the first polyoxyalkylene;
- (ii) a carrier liquid interacting with the biocompatible polymer to impart reverse-thermal viscosity behavior to the therapeutic composition;
- and
- (iii) a pharmaceutical substance selected from the group consisting of glutathione and a precursor for glutathione biosynthesis, the pharmaceutical substance being effective for treating the oral mucositis at a mucosal site within the oral cavity;
- wherein, during the introducing the therapeutic composition is at an administration temperature that is at least 1° C. and that is lower than the physicological temperature of the host, at the administration temperature the therapeutic composition being in the form of a solution comprising the pharmaceutical substance and the biocompatible polymer dissolved in the carrier liquid, and after the introducing, at least a portion of the biocompatible polymer and at least a portion of the pharmaceutical substance adhere to a mucosal surface at the mucosal site;
- and
- wherein, the therapeutic composition exhibits the reverse-thermal viscosity behavior over at least some range of temperatures between the administration temperature and the physiological temperature of the host.
Dependencies are inferred from the claim text.